A definitive cure for at least three of the top five deadliest cancers is approved before 2040.

Question

Six frontier AI models put this at 6% by 12 Oct 2076. Full reasoning from every model.

WillHappen.ai · Accepted Answer

6% — the median of 6 frontier models, resolving by 2076-10-12.

Answer

Gemini (Google): 4% — Top deadly cancers present extreme clonal heterogeneity that prevents single definitive curative approvals within 14 years. Lung, colorectal, pancreas, breast, and liver cancers rarely yield universal cures; standard FDA endpoints track OS not eradication. Phase I to approval takes 10-12 years, meaning candidate regimens curing 3 of 5 must already be entering clinics, which none are. mRNA vaccines and CAR-T will extend remission, but establishing definitive curative labels across three disparate types by 2040 fails.

Answer

Claude (Anthropic): 4% — Hinges on whether regulators ever label any lung/liver/colorectal/stomach/pancreatic therapy a 'definitive cure.' Cancer biology is heterogeneous and metastatic disease resists single curative mechanisms, so 'cure' language is avoided by FDA/EMA even for high-response therapies like… Current oncology progress is incremental (survival extension, remission rates) rather than categorical cures, and no top-5 killer (lung, liver, stomach, colorectal… Regulatory and scientific culture reserves 'cure' claims for cases with near-total eradication and long-term relapse-free data, a bar unmet by any current modality, even…

Answer

GPT (OpenAI): 27% — It hinges on whether durable cures can be demonstrated in common late-stage solid tumors, not just early detected disease. FDA approvals often establish meaningful survival gains, while definitive eradication across major solid-tumor populations is rare. Lung, colorectal, pancreatic, breast, and prostate cancer require separate pivotal trials and long follow-up before 2040. I would raise this sharply if phase III trials show long-term treatment-free survival in metastatic pancreatic or lung cancer.

Answer

Grok (xAI): 7% — No major solid-tumor cancer has a true pan-type cure; 13 years is too short for three. FDA/EMA must approve therapies that eradicate essentially all cases of three of lung/colorectal/liver/stomach/breast (or equivalent mortality ranking) by end-2039. Phase-3 oncology programs already running today will not finish and expand to pan-type curative claims before ~2035; new modalities start even later. Historical base rate is zero such approvals in 50 years; only a sudden, generalizable platform (e.g., universal neoantigen vaccine) would move the needle.

Answer

DeepSeek (DeepSeek): 15% — Curing three distinct major solid-tumor cancers with a single approved therapy in 14 years is orders of magnitude harder than any prior oncology benchmark. FDA has approved fewer than five outright cures for solid tumors in history; top killers are lung, colorectal, liver, pancreatic, stomach. Most likely path is CAR-T or gene-edited approaches in earlier lines; each needs 8-12 years from Phase I to approval. By 2040, seven or eight such products could plausibly clear FDA; but only highly selected subsets would be truly curative—not whole cancer types.

Answer

Qwen (Alibaba): 4% — "Definitive cure" for advanced solid tumors is a bar no therapy has cleared; needing three such approvals in 14 years is near-impossible. No advanced-stage solid tumor among lung, colorectal, liver, stomach, or breast cancer has ever been declared cured by a systemic therapy; base rate is zero. Even if a breakthrough platform (mRNA vaccine, universal CAR-T) enters Phase I in 2027, regulatory approval for three separate indications by 2040 requires parallel… The one development that would raise this materially: a pan-cancer mechanism (e.g., targeting a shared vulnerability like telomerase or a conserved neoantigen) showing…

A definitive cure for at least three of the top five deadliest cancers is approved before 2040.

An FDA-approved treatment that halts or reverses cognitive decline in Alzheimer's disease becomes available before 2036.

A broad-spectrum curative therapy for metastatic solid tumors is approved before 2035.

An mRNA-based therapeutic cancer vaccine receives full FDA approval for curative intent before 2032.

A universal cure or definitive therapeutic regimen eliminating all major human cancers is approved by a major regulatory agency before 2050.